Peptides News and Research

RSS

Molecule stops DNA replication in its tracks

When a dividing cell duplicates its genetic material, a molecular machine called a sliding clamp travels along the DNA double helix, tethering the proteins that perform the replication.

19 Oct 2008

Low levels of vitamin D linked to Parkinson's

Scientists in the U.S. have found that many people suffering from Parkinson's disease have inadequate levels of vitamin D compared to healthy people.

14 Oct 2008

Prevalence of vitamin D insufficiency in patients with Parkinson's and Alzheimer's disease

A majority of Parkinson's disease patients had insufficient levels of vitamin D in a new study from Emory University School of Medicine.

13 Oct 2008

FDA continues review of Takeda's NDA for Alogliptin

Takeda Pharmaceutical Company Limited has announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification that the U.S. Food and Drug Administration (FDA) will not be able to complete its review of the alogliptin New Drug Application (NDA) by the Prescription Drug User Fee Act (PDUFA) date of October 27, 2008.

12 Oct 2008

Use of oral vitamin D supplements may help prevent eczema

A study led by researchers at the University of California, San Diego School of Medicine suggests that use of oral Vitamin D supplements bolsters production of a protective chemical normally found in the skin, and may help prevent skin infections that are a common result of atopic dermatitis, the most common form of eczema.

6 Oct 2008

Discovery of 100 new antiangiogenesis peptides

Using computer models and live cell experiments, biomedical engineers at the Johns Hopkins University School of Medicine have discovered more than 100 human protein fragments that can slow or stop the growth of cells that make up new blood vessels.

5 Oct 2008

Pain is not a symptom of arthritis, pain causes arthritis

Pain is more than a symptom of osteoarthritis, it is an inherent and damaging part of the disease itself, according to a study published today in journal Arthritis and Rheumatism.

29 Sep 2008

Targeted nanoparticles map tumor blood supply in 3-D, assess therapy

One of the defining characteristics of solid tumors is the development of a network of new blood vessels to nourish the rapidly reproducing malignant cells. Now, using a nanoparticle targeted to those new blood vessels, a joint academic-industrial research team, led by investigators from the Siteman Center of Cancer Nanotechnology Excellence, has developed a way to construct a three-dimensional (3-D) map of tumor-induced angiogenesis and monitor the effects of drug therapies on those new blood vessels.

28 Sep 2008

Nanotubes detect tumors and deliver high-potency punch

Researchers at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (CCNE-TR), based at Stanford University, have found a new way to target cancer cells while leaving healthy cells untouched.

28 Sep 2008

Once a week treatment for type 2 diabetes in the pipeline

Canadian researchers have found that a weekly treatment for type 2 diabetes has proved safe and effective for patients.

8 Sep 2008

FDA 'fast track' granted to BioMS Medical for lead drug, dirucotide for the treatment of multiple sclerosis

BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.

4 Sep 2008

Fibrex medical reports positive phase II results for peptide for the treatment of reperfusion injury

Fibrex Medical has announced positive Phase II results for FX06, a peptide for the treatment of reperfusion injury - the damage to heart muscle that results from remedial treatment following a heart attack. The results will be presented at the ESC Congress today in Munich, Germany.

2 Sep 2008

Fibrin-derived peptide FX06 reduces cardiac reperfusion injury

Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack.

2 Sep 2008

New diagnostic tools and biomarkers

Patients presenting shortness of breath on arrival at the emergency department (ED) can gain from improved diagnosis allowing physicians to distinguish congestive heart failure patients from those presenting pneumonia.

1 Sep 2008

Advances in the management of diabetes mellitus

The need for long term studies to establish the best means of treating Diabetes, was underlined by Prof John Cleland from the University of Hull at the ESC Congress in Munich. Prof Cleland listed the latest treatment available for patients and voiced his concern about the side-effects and efficacy of available anti-diabetic drugs.

1 Sep 2008

Takeda and Affymax provide update for Hematide in chemotherapy-induced anemia

Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.

28 Aug 2008

Dual-mode nanoparticles image tumors using MRI and PET

Medical imaging represents one of the most used and useful procedures in the oncologist's diagnostic toolkit, even though each of the most useful techniques-magnetic resonance imaging (MRI), computerized tomography x-ray imaging (CT), and positron emission tomography (PET) scanning-has its own set of limitations.

17 Aug 2008

Sngle-walled carbon nanotubes used as cancer drug delivery vehicles

The problem with using a shotgun to kill a housefly is that even if you get the pest, you'll likely do a lot of damage to your home in the process. Hence the value of the more surgical flyswatter.

14 Aug 2008

Genetic biomarker linked to subcutaneous growth hormone dose-response

The interindividual variability of response to subcutaneously applied protein-based drugs remains poorly understood. However, defining genetic markers that can be associated with biological effects of such drugs may improve the understanding of individual variability of response and even drug resistance.

6 Aug 2008

Bionor Immuno trials new innovative therapeutic immunization designed to help existing HIV and AIDS patients

Bionor Immuno today announced that it has advanced its efforts to develop the first HIV therapeutic immunization with the dosing of patients in a global Phase 2b clinical trial of the company's lead candidate (Vacc-4x).

4 Aug 2008